Abstract 1019P
Background
The efficacy of immune checkpoint inhibitors (ICIs) in SMARCA4 mutant non-small cell lung cancer (NSCLC) is limited. CD8+ T cell exhaustion plays an important role in damaging anti-tumor immunity, but the molecular mechanisms remain unclear.
Methods
We compared the survival difference between patients with SMARCA4 mutation and wild type. The RNA sequencing of CD8+T cells sorted from tumor tissues was performed. The SMARCA4 mutant-H1299 cells were implanted into the left flank of the NSG mice. 2×107 human PBMCs were separated and injected intravenously into NSG mice to establish humanized NSG mouse models. Anti-PD-1 of Bispecific PD1-IL2 antibody were given intraperitoneally. The frequencies and phenotypes of CD8+T cells in mouse spleens and blood were detected by flow cytometry while those in tumor tissues were determined by multiplex immunofluorescence (mIF). The mIF staining was performed to validate differences of CD8+ T cells exhaustion phenotype between SMARCA4 mutant and wild-type patient tissues.
Results
Treatment with ICIs could not improve outcomes in patients with SMARCA4 mutations (P = 0.754). The analysis of RNA sequencing showed that the production of interleukin-2 (IL-2) was significantly reduced in CD8+T cells of SMARCA4 mutant Lewis lung carcinoma (P < 0.001). The analysis of mIF revealed that the infiltration of PD1+CD8+, LAG3+CD8+, TIM3+CD8+ T cells increased in SMARCA4 mutant tumor tissues. We found that a high level of IL-2 leads to the persistent activation of STAT5 in CD8+ T cells. Bispecific PD1-IL2 antibody enhanced anti-tumor immunity and suppressed tumor progression by reversing CD8+T cells exhaustion.
Conclusions
The PD1-IL2 bispecific antibody could reverse CD8+T cell exhaustion to enhance anti-tumor immunity in SMARCA4 mutant NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H. Wang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
907P - Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Denis Soulieres
Session: Poster session 03
909P - Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial
Presenter: Alix Marhic
Session: Poster session 03
911P - Association of genomic landscape and plasma protein dynamic changes with clinical outcome in patients with R/M HNSCC treated with pembrolizumab with nab-paclitaxel and platinum
Presenter: Xinrui Chen
Session: Poster session 03
912P - Selection of personalized salvage treatments in advanced refractory head and neck squamous cell carcinomas via multi-omics tumor profiling
Presenter: Ramin Ajami
Session: Poster session 03
913P - Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer
Presenter: Juan Carlos Redondo González
Session: Poster session 03
914P - The landscape of somatic copy number alterations of head and neck squamous cell carcinoma across different anatomic sites
Presenter: Juan Carlos Redondo González
Session: Poster session 03
915P - Longer OS and RFS for CD3high/PD-L1+ head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Simon Laban
Session: Poster session 03
916P - Deep spatial profiling of head and neck squamous cell carcinoma offers insights into the tumor microenvironment of hpv-stratified patients
Presenter: Abhishek Aggarwal
Session: Poster session 03